Contents

Volume 72 Supplement 2 | ARD April 2013

Advances in targeted therapies XIV

Preface

ii1 Advances in targeted therapies XIV
F C Breedveld, J K Kalden, J S Smolen

Consensus statement

ii2 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012

ii35 Documentation of off-label use of biologics in Rheumatoid Arthritis
D E Farr, R Fässmann, J Kalden, A Kanaanough, J Supe, P Mease, J Smolen, F Breedveld

Papers

ii52 Bone remodelling in inflammatory arthritis
S R Goldberg, P E Pavlic, T N Crimi, T Show, M R Flannery, N B Binder, F P Rose, R M McGuck

ii56 Recent insights into the genetic basis of systemic lupus erythematosus
O J Huda, B P Tsao

ii62 Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis?
C G M Kaldenberg

ii66 Recent progress in conventional and biologic therapy for systemic lupus erythematosus
D Wofsy

ii69 Advances in sonographic scoring of rheumatoid arthritis
S Ohrndorf, M Backhaus

ii76 Neuropsychiatric manifestations in patients with systemic lupus erythematosus: epidemiology and radiology pointing to an immune-mediated cause
S A Yazdi, S K Drexler

ii80 Cytokine-producing B cells as regulators of pathogenic and protective immune responses
S Pillai

ii85 Regulatory cell subsets in the control of autoantibody production related to systemic autoimmunity
K Fujio, T Okamura, S Santomo, K Yamamoto

ii90 MicroRNA-146a in autoimmunity and innate immune responses
E K L Chan, A Ceribelli, M Sanfilippo

ii96 Regulation of interleukin 1α secretion by inflammasomes
A S Yatsu, S K Drexler

i100 Implications of anti-cytokine therapy in coloberal cancer and autoimmune diseases
K Wang, S G Cousins, K Kan

ii104 Biomarkers in psoriasis and psoriatic arthritis
F Villanova, P D Meglio, F O Nolte

ii111 Janus kinase inhibitors in autoimmune diseases
J J O’Shea, A Kontzias, K Yamaoka, Y Tanaka, A Lawrence

ii116 Effect of IL-17A blockade with secukinumab in autoimmune diseases
D P Pitt, D M Lee, P Kollberg, C Antoni

ii124 Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?
Y Tanaka

ii128 Quality indicators in rheumatoid arthritis care: using measurement to promote quality improvement
I. Czernok, S Mau

i132 Autoimmunity in rheumatoid arthritis: different antigens—common principles
L A Trouw, T W J Huizinga, R E M Toes

This article is produced by the Editor to be of special interest or importance and is freely available online.

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme. See http://ard.bmj.com/site/about/guidelines.xhtml#open

Ann Rheum Dis: first published as on 1 April 2013. Downloaded from http://ard.bmj.com on July 16, 2023 by guest.